Regulation of Androgen Receptor Activity by Tyrosine Phosphorylation (DOI:10.1016/j.ccr.2006.08.021);Regulation of androgen receptor activity by tyrosine phosphorylation

Cancer Cell

Volumn 10, Issue 4, 2006, Pages 309-319

  Guo, Zhiyong ^a   Dai, Bojie ^a   Jiang, Tianyun ^a   Xu, Kexin ^a   Xie, Yingqiu ^a   Kim, Oekyung ^a   Nesheiwat, Issa ^a   Kong, Xiangtian ^b   Melamed, Jonathan ^b   Handratta, Venkatesh D ^a   Njar, Vincent C O ^a   Brodie, Angela M H ^a   Yu, Li Rong ^c   Veenstra, Timothy D ^c   Chen, Hegang ^a   Qiu, Yun ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

CELLCYCLE

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GROWTH FACTOR; TYROSINE;

ANDROGEN ABLATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; HORMONAL REGULATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 33749445413     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.12.010     Document Type: Erratum

References (41)

1. Bartlett J.M., Brawley D., Grigor K., Munro A.F., Dunne B., and Edwards J. Type I receptor tyrosine kinases are associated with hormone escape in prostate cancer. J. Pathol. 205 (2005) 522-529
2. Bellido T., Jilka R.L., Boyce B.F., Girasole G., Broxmeyer H., Dalrymple S.A., Murray R., and Manolagas S.C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J. Clin. Invest. 95 (1995) 2886-2895
3. Berns E.M., de Boer W., and Mulder E. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 9 (1986) 247-259
4. Biscardi J.S., Ishizawar R.C., Silva C.M., and Parsons S.J. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2 (2000) 203-210
5. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., and Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004) 33-39
6. Craft N., Shostak Y., Carey M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5 (1999) 280-285
7. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., and Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54 (1994) 5474-5478
8. Culig Z., Hobisch A., Bartsch G., and Klocker H. Androgen receptor-an update of mechanisms of action in prostate cancer. Urol. Res. 28 (2000) 211-219
9. Debes J.D., and Tindall D.J. Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351 (2004) 1488-1490
10. Denmeade S.R., and Isaacs J.T. A history of prostate cancer treatment. Nat. Rev. Cancer 2 (2002) 389-396
11. Di Lorenzo G., Tortora G., D'Armiento F.P., De Rosa G., Staibano S., Autorino R., D'Armiento M., De Laurentiis M., De Placido S., Catalano G., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8 (2002) 3438-3444
12. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 (2001) 34-45
13. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20 (2002) 3001-3015
14. George D.J., Halabi S., Shepard T.F., Sanford B., Vogelzang N.J., Small E.J., and Kantoff P.W. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin. Cancer Res. 11 (2005) 1815-1820
15. Gioeli D., Ficarro S.B., Kwiek J.J., Aaronson D., Hancock M., Catling A.D., White F.M., Christian R.E., Settlage R.E., Shabanowitz J., et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277 (2002) 29304-29314
16. Gregory C.W., Fei X., Ponguta L.A., He B., Bill H.M., French F.S., and Wilson E.M. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 279 (2004) 7119-7130
17. Harvey J.M., Clark G.M., Osborne C.K., and Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17 (1999) 1474-1481
18. Heinlein C.A., and Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25 (2004) 276-308
19. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730
20. Krueckl S.L., Sikes R.A., Edlund N.M., Bell R.H., Hurtado-Coll A., Fazli L., Gleave M.E., and Cox M.E. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res. 64 (2004) 8620-8629
21. Lee L.F., Guan J., Qiu Y., and Kung H.J. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol. Cell. Biol. 21 (2001) 8385-8397
22. Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., and Gao A.C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 9 (2003) 370-376
23. Lee L.F., Louie M.C., Desai S.J., Yang J., Chen H.W., Evans C.P., and Kung H.J. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23 (2004) 2197-2205
24. Lin H.K., Yeh S., Kang H.Y., and Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA 98 (2001) 7200-7205
25. Long B.J., Grigoryev D.N., Nnane I.P., Liu Y., Ling Y.Z., and Brodie A.M. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer Res. 60 (2000) 6630-6640
26. Lorenzo G.D., Bianco R., Tortora G., and Ciardiello F. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin. Prostate Cancer 2 (2003) 50-57
27. Migliaccio A., Castoria G., Di Domenico M., de Falco A., Bilancio A., Lombardi M., Barone M.V., Ametrano D., Zannini M.S., Abbondanza C., and Auricchio F. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J. 19 (2000) 5406-5417
28. Olea N., Sakabe K., Soto A.M., and Sonnenschein C. The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126 (1990) 1457-1463
29. Shang Y., Myers M., and Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 9 (2002) 601-610
30. Steiner H., Godoy-Tundidor S., Rogatsch H., Berger A.P., Fuchs D., Comuzzi B., Bartsch G., Hobisch A., and Culig Z. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am. J. Pathol. 162 (2003) 655-663
31. Taplin M.-E., Rajeshkumar B., Halabi S., Werner C.P., Woda B.A., Picus J., Stadler W., Hayes D.F., Kantoff P.W., Vogelzang N.J., and Small E.J. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and leukemia group B study 9663. J. Clin. Oncol. 21 (2003) 2673-2678
32. Titus M.A., Gregory C.W., Ford III O.H., Schell M.J., Maygarden S.J., and Mohler J.L. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin. Cancer Res. 11 (2005) 4365-4371
33. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11 (2005) 4653-4657
34. Ueda T., Mawji N.R., Bruchovsky N., and Sadar M.D. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J. Biol. Chem. 277 (2002) 38087-38094
35. Veldscholte J., Ris-Stalpers C., Kuiper G.G., Jenster G., Berrevoets C., Claassen E., van Rooij H.C., Trapman J., Brinkmann A.O., and Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173 (1990) 534-540
36. Yeatman T.J. A renaissance for SRC. Nat. Rev. Cancer 4 (2004) 470-480
37. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., and Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96 (1999) 5458-5463
38. Yu L.R., Conrads T.P., Uo T., Kinoshita Y., Morrison R.S., Lucas D.A., Chan K.C., Blonder J., Issaq H.J., and Veenstra T.D. Global analysis of the cortical neuron proteome. Mol. Cell. Proteomics 3 (2004) 896-907
39. Zegarra-Moro O.L., Schmidt L.J., Huang H., and Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62 (2002) 1008-1013
40. Zhao X.Y., Malloy P.J., Krishnan A.V., Swami S., Navone N.M., Peehl D.M., and Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6 (2000) 703-706
41. Zhou Z.X., Kemppainen J.A., and Wilson E.M. Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 9 (1995) 605-615